Page 9 of 21

EN4.31 | Nasopharyngeal Angiofibroma — SDL Guide (Part 2)

Diagnosis and Differential Diagnosis

The diagnosis of JNA is made on clinical grounds (adolescent male + recurrent severe epistaxis + progressive unilateral nasal obstruction) confirmed by characteristic contrast CT imaging. No tissue biopsy is required or appropriate before surgery. The diagnosis is secure when the clinical profile matches and CT demonstrates the brightly enhancing nasopharyngeal mass with the Holman-Miller sign. The histological confirmation is obtained from the resection specimen after surgical excision. Arriving at the diagnosis of JNA requires systematic exclusion of other conditions that can present with a unilateral nasal mass in a young patient. The diagnostic approach is driven by the imaging characteristics — specifically, whether the mass is vascular (brightly enhancing on contrast CT) or avascular, whether the Holman-Miller sign is present, whether bony erosion or destruction is seen (which would raise the possibility of malignancy), and whether the mass arises from the posterolateral nasal wall and sphenopalatine foramen region. Each differential has a distinctive profile on CT that narrows the diagnosis even before histology.

Differential diagnosis of unilateral vascular nasal mass in a young patient:

• Antrochoanal polyp: smooth, pale or greyish, non-vascular, unilateral, arises from maxillary antrum, extends to choana. Common in children and young adults. Does not bleed massively on probing. CT shows bilobed non-enhancing cystic mass, not a brightly enhancing solid mass.
• Nasal haemangioma / vascular malformation: may present as a reddish mass with epistaxis, but does not have the characteristic Holman-Miller sign and CT appearance of JNA. Histology required for definitive distinction.
• Inverted (Schneiderian) papilloma: unilateral, arises from lateral nasal wall; may have a warty or irregular surface; not as massively vascular; not specifically adolescent males. Biopsy required to exclude malignant transformation — but note: do not biopsy if JNA is a possibility until JNA is excluded by CT.
• Rhabdomyosarcoma: malignant soft-tissue sarcoma of the head and neck in children and adolescents; may present with nasal mass and epistaxis; rapidly progressive, may invade bone; distinguished from JNA by CT showing bone destruction, younger age group (peak <10 years), no Holman-Miller sign. Requires biopsy for diagnosis — but only after JNA has been excluded by imaging.
• Nasopharyngeal carcinoma (NPC): occurs in older adolescents and young adults in endemic areas (Southeast Asia, North Africa); unilateral cervical lymphadenopathy, nasal obstruction, epistaxis, cranial nerve palsies (CN VI most common — 'Trotter's triad'). CT shows a mass in the nasopharynx but without the characteristic enhancement and bowing of JNA. Biopsy is required for NPC diagnosis.

The clinical principle is: in an adolescent male with severe epistaxis and a unilateral vascular nasal mass, order contrast CT first. If CT confirms JNA characteristics, manage as JNA — no biopsy. If CT is atypical for JNA, reconsider the differential and proceed to MRI and possibly biopsy under controlled conditions (operating theatre, with blood available).

Principles of Management of JNA

The management of JNA is primarily surgical, with pre-operative embolisation as the essential preparatory step. The choice of surgical approach is determined by tumour stage. Adjuncts such as radiotherapy are reserved for specific indications. Hormone therapy, once used, is now of historical interest only.

Pre-operative embolisation: Selective catheter angiography is performed under fluoroscopic guidance, the dominant feeding vessels (primarily from the internal maxillary artery, a terminal branch of the external carotid artery) are identified, and embolic material (PVA particles, coils, or gelatin sponge) is injected to occlude them. The procedure is performed 24–48 hours before surgery — the interval allows the embolic effect to consolidate while preventing revascularisation. Embolisation reduces intraoperative blood loss typically by 50–75%. If intracranial extension is present with internal carotid artery feeding vessels, embolisation of ICA branches requires specialised neurointerventional expertise.

Surgical approaches by stage:

Stage	Extent	Preferred Surgical Approach
Stage I	Nasal cavity / nasopharynx only	Endoscopic transnasal excision
Stage II	Pterygomaxillary fossa / paranasal sinuses	Endoscopic or combined endoscopic-transpalatal; or Denker's approach (extended transnasal)
Stage II (infratemporal fossa)	Infratemporal fossa extension	Transpalatal, lateral rhinotomy, or infratemporal fossa approach
Stage III	Orbital / parasellar extension	Combined endoscopic + external (midfacial degloving or Le Fort I osteotomy)
Stage IV	Intracranial extension	Craniofacial approach with neurosurgical collaboration

Endoscopic surgery (FESS-based transnasal approach) has become the standard for Stages I and II in specialised centres, offering lower morbidity, excellent visualisation, and equivalent recurrence rates to open approaches. However, it requires expert endoscopic surgeons and adequate haemostasis setup.

Radiotherapy: Reserved for: unresectable intracranial extension; residual or recurrent disease after surgery not amenable to re-excision; or patients who refuse surgery. Radiotherapy is generally avoided as primary treatment in adolescent males because of the long-term risk of radiation-induced malignancy, growth disturbance, and cataract formation in this young age group.

Recurrence: Occurs in approximately 20% of cases after surgical excision. Recurrence is most common in Stage III–IV disease with residual tumour at the skull base. Post-operative MRI at 3 months and annually thereafter detects recurrence early. Recurrent disease is managed with re-excision (if feasible) or radiotherapy.

Spontaneous regression: Documented in small Stage I tumours in post-pubertal males (consistent with the hormonal hypothesis), but not sufficiently predictable to form the basis of clinical management — surgery remains the standard.

Self-Assessment: Nasopharyngeal Angiofibroma

Test your clinical reasoning on these JNA scenarios before proceeding to the self-check questions.

Scenario 1: A 13-year-old boy is referred to you by a general practitioner with a note saying 'Nasal polyp — please excise.' He has had two episodes of severe left-sided epistaxis requiring hospital admission for nasal packing. Anterior rhinoscopy shows a fleshy, reddish, pulsatile-looking mass in the left nasal cavity. What do you do before any surgical intervention, and what should you tell the referring doctor?

Expected answer: Order contrast CT (and MRI) of the paranasal sinuses and skull base before any intervention. The clinical profile — adolescent male, severe recurrent epistaxis, unilateral vascular nasal mass — is JNA until proven otherwise. The referring doctor should be informed that biopsy is contraindicated and no surgical excision should occur until imaging confirms the diagnosis and a plan for pre-operative embolisation is arranged. Labelling this as a 'nasal polyp' is potentially dangerous.

Scenario 2: After pre-operative embolisation, a Stage II JNA is successfully excised endoscopically. The patient is discharged on day 2. When do you schedule follow-up imaging, and what are you looking for?

Expected answer: MRI of the nasopharynx and skull base at approximately 3 months post-operatively to assess for residual tumour at the skull base (the most difficult area to clear completely, particularly in Stage II with pterygomaxillary fossa involvement). Annual MRI surveillance for at least 2–3 years thereafter, as recurrences can be detected before they become symptomatic. Recurrence rate is approximately 20%; early detection allows curative re-excision.

Scenario 3: A 15-year-old with JNA is being counselled about treatment. His family asks whether 'watchful waiting' is an option because they have read that the tumour sometimes 'goes away on its own.' What is the evidence-based answer?

Expected answer: Spontaneous regression is documented in a small number of cases (typically small Stage I tumours in older adolescents/post-pubertal males), and is consistent with the hormonal (testosterone-dependent growth) hypothesis. However, the regression rate is not predictable enough to form the basis of clinical management. Progressive growth and increasing epistaxis severity is the more common natural history. Surgery after pre-operative embolisation is the standard of care. 'Watchful waiting' may be considered only for very small Stage I disease in a post-pubertal male with minor symptoms under close surveillance — not as a default for all patients.